IMVT

Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn  

Retrieved on: 
Wednesday, September 28, 2022
IMVT, Safety, Human, Graves' disease, Hemolytic anemia, COVID-19, LDL, FDA, Polyneuropathy, NEW, IND, Company, Graves' ophthalmopathy, Immunoglobulin G, Growth, Calendar, U.S. Securities and Exchange Commission, Patient, Technology, Annual report, Nasdaq, Investor relations, Private Securities Litigation Reform Act, Degenerative disease, Security (finance), GLOBE, SEC, Pharmaceutical industry, Rheumatology, Myasthenia gravis, Hematology

The combined franchise of batoclimab and IMVT-1402 may enable multiple paths to enhanced value creation for Immunovant.

Key Points: 
  • The combined franchise of batoclimab and IMVT-1402 may enable multiple paths to enhanced value creation for Immunovant.
  • All forward-looking statements are based on estimates and assumptions by Immunovants management that, although Immunovant believes to be reasonable, are inherently uncertain.
  • All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expected.
  • Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Immunovant Receives $200 Million Strategic Investment from Roivant Sciences

Retrieved on: 
Monday, August 2, 2021
Roivant Sciences, IMVT, Pro forma

NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it has received a $200 million strategic investment from Roivant Sciences.

Key Points: 
  • NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it has received a $200 million strategic investment from Roivant Sciences.
  • Immunovant intends to use the proceeds from this investment to advance the development of IMVT-1401 in multiple indications.
  • After giving effect to the investment, Immunovant has a pro forma cash balance of approximately $600 million and Roivant has increased its ownership stake in Immunovant from 57.5% to 63.8%, based on Immunovants cash balance and share count as of March 31, 2021.
  • We are incredibly excited about the prospects for IMVT-1401, and we are eager to support Immunovant through this investment.

IMVT INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc.

Retrieved on: 
Wednesday, April 7, 2021
Bernstein, IMVT, Lawsuit

On February 2, 2021, Immunovant issued a press release announc[ing] a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.

Key Points: 
  • On February 2, 2021, Immunovant issued a press release announc[ing] a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 20, 2021.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

IMVT INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc.

Retrieved on: 
Monday, March 29, 2021
Bernstein, IMVT, Lawsuit

On February 2, 2021, Immunovant issued a press release announc[ing] a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.

Key Points: 
  • On February 2, 2021, Immunovant issued a press release announc[ing] a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 20, 2021.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

IMVT INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc.

Retrieved on: 
Sunday, March 7, 2021
Bernstein, IMVT, Lawsuit

On February 2, 2021, Immunovant issued a press release announc[ing] a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.

Key Points: 
  • On February 2, 2021, Immunovant issued a press release announc[ing] a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 20, 2021.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

The Law Offices of Frank R. Cruz Announces Investigation of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT) on Behalf of Investors

Retrieved on: 
Tuesday, February 23, 2021
Legal, Professional services, Lluís Companys, IMVT, NASDAQ, Finance, Spanish politicians, Government of Spain

The Law Offices of Frank R. Cruz announces an investigation of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant", or the Company) (NASDAQ: IMVT ) on behalf of investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz announces an investigation of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant", or the Company) (NASDAQ: IMVT ) on behalf of investors concerning the Companys possible violations of federal securities laws.
  • On February 2, 2021, the Company issued a press release announc[ing] a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.
  • On this news, the Companys stock price fell $18.22 per share, or 42.08%, to close at $25.08 per share on February 2, 2021, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT) on Behalf of Investors

Retrieved on: 
Tuesday, February 23, 2021
Legal, Professional services, Lluís Companys, IMVT, NASDAQ, Finance, Spanish politicians, Government of Spain

Law Offices of Howard G. Smith announces an investigation on behalf of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant", or the Company) (NASDAQ: IMVT ) investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant", or the Company) (NASDAQ: IMVT ) investors concerning the Companys possible violations of federal securities laws.
  • On February 2, 2021, the Company issued a press release announc[ing] a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.
  • On this news, the Companys stock price fell $18.22 per share, or 42.08%, to close at $25.08 per share on February 2, 2021, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401

Retrieved on: 
Tuesday, February 2, 2021
Health, Autoimmune diseases, Branches of biology, Myasthenia gravis, IMVT, Cholesterol, Clinical trial, Myasthenia

NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.

Key Points: 
  • NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.
  • Cholesterol levels were not measured in prior clinical trials of IMVT-1401 in Myasthenia Gravis (MG) and in healthy subjects.
  • In this study, cholesterol parameters are assessed at baseline, at twelve weeks, and at week 20 following eight weeks off drug.
  • Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Ligand OmniAb® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis

Retrieved on: 
Tuesday, August 25, 2020
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Autoimmune diseases, Myasthenia, IMVT, OmniAb®, Immunovant, Inc., Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) OmniAb partner Immunovant, Inc. (NASDAQ: IMVT) announced positive topline results from ASCEND MG, a Phase 2a study of OmniAb-derived IMVT-1401 in patients with myasthenia gravis (MG).

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) OmniAb partner Immunovant, Inc. (NASDAQ: IMVT) announced positive topline results from ASCEND MG, a Phase 2a study of OmniAb-derived IMVT-1401 in patients with myasthenia gravis (MG).
  • We are proud of the ongoing work by Immunovant and the strong results demonstrated by IMVT-1401 in patients who suffer with myasthenia gravis.
  • We have a growing OmniAb partner base with an increasing number of late-stage programs with important upcoming clinical or regulatory events.
  • Immunovant plans to initiate a Phase 3 registration study with IMVT-1401 for the treatment of myasthenia gravis in the first half of 2021.

Immunovant Announces Positive Topline Results from Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Myasthenia Gravis

Retrieved on: 
Tuesday, August 25, 2020
IMVT, Placebo, Articles

Results from the six-week treatment period included three arms: 340 mg IMVT-1401 weekly (N=5), 680 mg IMVT-1401 weekly (N=5), and placebo (N=5).

Key Points: 
  • Results from the six-week treatment period included three arms: 340 mg IMVT-1401 weekly (N=5), 680 mg IMVT-1401 weekly (N=5), and placebo (N=5).
  • MG-ADL responder rates, defined as the percentage of patients showing a > 2-point improvement, were 60% for IMVT-1401-treated patients vs. 20% for placebo.
  • We are absolutely thrilled with the results of this trial, said Pete Salzmann, M.D., Chief Executive Officer of Immunovant.
  • Importantly, IMVT-1401 was delivered by subcutaneous injection, opening the future possibility of at-home, self-administered treatment rather than infusion center-based treatment.